Together, the genetic ablation of DYRK1A in adult cardiomyocytes recapitulated the effects of LCTB-92 treatment after MI, further supporting the potential therapeutic benefits DYRK1A inhibition after MI. Here, DYRK1A is linked to myocardial infarction.